OCCUPATION AND HEALTH ›› 2023, Vol. 39 ›› Issue (21): 2965-2969.

• Treatise • Previous Articles     Next Articles

Safety evaluation on poliomyelitis related vaccines in Pudong New Area of Shanghai from 2016-2021

ZHOU Cuiping, WANG Weiping, LIU Wenmin, DENG Pengfei, FEI Yi   

  1. Department of Immunology,Pudong New Area Center for Disease Control and Prevention in Shanghai,Shanghai 200136,China
  • Received:2023-02-10 Revised:2023-04-24 Online:2023-11-01 Published:2026-03-26
  • Contact: FEI Yi,Chief physician,E-mail:yfei@pdcdc.sh.cn

Abstract: Objective To analyze the characteristics of adverse events following immunization(AEFI) of poliomyelitis related vaccines in Pudong New Area of Shanghai from 2016 to 2021,evaluate the immunization safety related to polio vaccines. Methods The data on AEFI cases of bivalent oral poliovirus vaccine(bOPV),sabin strain inactivated poliovirus vaccine[IPV(sabin)],salk strain inactivated poliovirus vaccine(IPV),diphtheria,tetanus,acellular pertussis,inactivated poliovirus and Haemophilus influenza type b combined vaccine(DTaP-IPV-Hib) in Pudong New Area of Shanghai from 2016 to 2021 were collected through the Chinese AEFI information system,and analyzed by descriptive epidemiological methods. Results A total of 3 262 AEFI cases of poliomyelitis related vaccines were reported in Shanghai Pudong New Area from 2016 to 2021(286.93/100 000 doses). The reported incidence of AEFI of bOPV,IPV(sabin),IPV(salk) and DTap-IPV-Hib was 12.03,78.74,90.30 and 1 075.75(χ2=7 166.67, P<0.05). Of all the AEFI reported,99.63% were common reactions and 0.31% rare ones(most of the reported cases were anaphylactic rashes). Most of the reported AEFI cases were children <1 year old. 55.61% of the reported cases occurred after first or second dose/time,AEFI incidence rates for bOPV mainly occurred after third or fourth dose/time. 96.87% of the reported cases occurred within 48 h following vaccination. Conclusion The poliomyelitis related vaccines in Pudong New Area of Shanghai have a good safety.

Key words: Poliomyelitis vaccine, Adverse events following immunization, Safety

CLC Number: